On June 4, 2019 IMV Inc. ("IMV" or the "Corporation") (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, reported that it will hold a conference call and webcast on Wednesday, June 12, 2019, at 8:00 a.m. ET (Press release, IMV, JUN 4, 2019, View Source [SID1234536878]). This call will provide an update on its ongoing phase 2 clinical trials with Merck’s Keytruda in diffuse large B-cell lymphoma (DLBCL).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Financial analysts are invited to join the conference call by dialing (866) 211-2304 (U.S. and Canada) or (647) 689-6600 (International) using the conference ID: 9685423

Other interested parties will be able to access the live audio webcast at this link: View Source The webcast will be recorded and made available on the IMV website for 30 days following the call.